MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease

    H. Ito, T. Kamei (Fujisawa, Japan)

    Objective: To evaluate the efficacy of istradefylline, a selective adenosine A2A receptor antagonist, for fatigue and depression in Parkinson's disease (PD) patients. Background: Istradefylline is…
  • 2016 International Congress

    Voice harmonic amplitude differences before and after LSVT LOUDTM in Parkinson’s disease

    M.P. Cannito, L.O. Ramig, A.E. Halpern, J.L. Spielman (Lafayette, LA, USA)

    Objective: To evaluate voice harmonic amplitudes from acoustic spectra of speech produced by subjects with Parkinson's disease (PD) before and after voice treatment, in order…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human

    M. Nomoto, M. Nagai, N. Nishikawa, K. Yano, Y. Kagamiishi, M. Akisada, S. Saito, M. Yuba, T. Koyanagi, A. Takeda (Tohon Ehime, Japan)

    Objective: The objective of this study was to characterize pharmacokinetic profile of levodopa prodrug ONO-2160 in animal and human. Background: Motor complications of Parkinson's disease…
  • 2016 International Congress

    Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

    M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

    Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death,…
  • 2016 International Congress

    Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?

    E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva, F.K. Shermukhamedova (Taskent, Uzbekistan)

    Objective: To study of Pisa syndrome in Parkinson's disease. Background: Although Pisa syndrome and scoliosis are sometimes used interchangeably to describe a laterally flexed postural…
  • 2016 International Congress

    Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

    R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

    Objective: To provide suggested guidance on how to select appropriate candidates for therapy with carbidopa/levodopa enteral suspension (CLES) based on published literature. Background: The introduction…
  • 2016 International Congress

    New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

    Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)

    Objective: To establish the simple therapeutic algorithm for abnormal posture in Parkinson's disease (PD) or related disorders. Background: Camptocormia or dropped head are sometimes accompanied…
  • 2016 International Congress

    Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes

    Y.O. Trufanov (Kyiv, Ukraine)

    Objective: To analyze the frequency and severity of swallowing difficulties in patients with Parkinson's disease (PD) and Parkinsonian syndromes. Background: Swallowing difficulties are common in…
  • 2016 International Congress

    Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

    S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

    Objective: To determine which factors predict medication reduction for Parkinson's disease (PD) patients after deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN). Background:…
  • « Previous Page
  • 1
  • …
  • 1918
  • 1919
  • 1920
  • 1921
  • 1922
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley